...
首页> 外文期刊>Cell death & disease. >Ligand-activated peroxisome proliferator-activated receptor-δ and -γ inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1
【24h】

Ligand-activated peroxisome proliferator-activated receptor-δ and -γ inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1

机译:配体激活的过氧化物酶体增殖物激活的受体-δ和-γ通过上调SIRT1抑制脂多糖引发的高迁移率族1的释放

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Peroxisome proliferator-activated receptors (PPARs) inhibit lipopolysaccharide (LPS)-primed release of high mobility group box 1 (HMGB1), a late proinflammatory mediator, but the underlying molecular mechanism is not completely understood. In this study, we demonstrated that the inhibition of HMGB1 release by PPAR- δ and - γ is associated with the deacetylase activity of SIRT1. Ligand-activated PPAR- δ and - γ inhibited LPS-primed release of HMGB1, concomitant with elevation in SIRT1 expression and promoter activity. These effects were significantly reduced in the presence of small interfering (si)RNAs against PPAR, indicating that PPAR- δ and - γ are involved in both HMGB1 release and SIRT1 expression. In addition, modulation of SIRT1 expression and activity by siRNA or chemicals correspondingly influenced the effects of PPARs on HMGB1 release, suggesting a mechanism in which SIRT1 modulates HMGB1 release. Furthermore, we showed for the first time that HMGB1 acetylated in response to LPS or p300/CBP-associated factor (PCAF) is an effective substrate for SIRT1, and that deacetylation of HMGB1 is responsible for blockade of HMGB1 release in macrophages. Finally, acetylation of HMGB1 was elevated in mouse embryonic fibroblasts from SIRT1 -knockout mice, whereas this increase was completely reversed by ectopic expression of SIRT1. These results indicate that PPAR-mediated upregulation of SIRT1 modulates the status of HMGB1 acetylation, which, in turn, has a critical role in the cellular response to inflammation through deacetylation-mediated regulation of HMGB1 release. Cell Death and Disease (2014) 5, e1432;; doi: 10.1038/cddis.2014.406 ; published online 2 October 2014
机译:过氧化物酶体增殖物激活受体(PPAR)抑制脂多糖(LPS)引发的高迁移率族盒1(HMGB1)(晚期促炎性介质)的释放,但其潜在的分子机制尚不完全清楚。在这项研究中,我们证明了PPAR-δ和-γ抑制HMGB1释放与SIRT1的脱乙酰酶活性有关。配体激活的PPAR-δ和-γ抑制LPS引发的HMGB1释放,并伴随SIRT1表达和启动子活性的升高。在存在针对PPAR的小干扰(si)RNA的情况下,这些作用显着降低,表明PPAR-δ和-γ与HMGB1释放和SIRT1表达有关。此外,siRNA或化学物质对SIRT1表达和活性的调节相应地影响了PPAR对HMGB1释放的影响,提示SIRT1调节HMGB1释放的机制。此外,我们首次证明响应LPS或p300 / CBP相关因子(PCAF)乙酰化的HMGB1是SIRT1的有效底物,而HMGB1的脱乙酰作用则是阻断巨噬细胞中HMGB1的释放。最后,在来自SIRT1-敲除小鼠的小鼠胚胎成纤维细胞中,HMGB1的乙酰化升高,而异位表达SIRT1完全逆转了这种增加。这些结果表明,PPAR介导的SIRT1上调可调节HMGB1乙酰化的状态,进而通过脱乙酰基介导的HMGB1释放调节而在细胞对炎症的反应中起关键作用。 Cell Death and Disease(2014)5,e1432; doi:10.1038 / cddis.2014.406; 2014年10月2日在线发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号